Abstract
The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Current Medicinal Chemistry
Title:Clinical and Marketed Proteasome Inhibitors for Cancer Treatment
Volume: 20 Issue: 20
Author(s): Jiankang Zhang, Peng Wu and Yongzhou Hu
Affiliation:
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Abstract: The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Export Options
About this article
Cite this article as:
Zhang Jiankang, Wu Peng and Hu Yongzhou, Clinical and Marketed Proteasome Inhibitors for Cancer Treatment, Current Medicinal Chemistry 2013; 20 (20) . https://dx.doi.org/10.2174/09298673113209990122
DOI https://dx.doi.org/10.2174/09298673113209990122 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On the Structural Basis of the Hypertensive Properties of Angiotensin II: A Solved Mystery or a Controversial Issue?
Current Topics in Medicinal Chemistry Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Translocator Protein 18-kDa: A Promising Target to Treat Neuroinflammation- related Degenerative Diseases
Current Medicinal Chemistry Learning from Metabolic Networks: Current Trends and Future Directions for Precision Medicine
Current Medicinal Chemistry Discovery and Development of Pyrazole-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Meet Our Editor-in-Chief
Current Psychopharmacology Aminoquinoline Melanin-Concentrating Hormone 1-Receptor (MCH1-R) Antagonists
Current Topics in Medicinal Chemistry Synthesis of New 3-heteroaryl-2-phenylquinolines and their Pharmacological Activity as Antimicrobial Agents
Letters in Organic Chemistry HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Preparation, In Vitro Screening and Molecular Modelling of Monoquaternary Compounds Related to the Selective Acetylcholinesterase Inhibitor BW284c51
Medicinal Chemistry Glutamate Binding-Site Ligands of NMDA Receptors
Current Medicinal Chemistry Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
Current Cancer Drug Targets Development of 5-Fluorouracil Derivatives as Anticancer Agents
Current Medicinal Chemistry Recovery of a 91-year-old COVID-19 Patient with Medical and Psychological Support
Current Chinese Science Synthesis of Novel Test Compounds for Antiviral Chemotherapy of Severe Acute Respiratory Syndrome (SARS)
Current Medicinal Chemistry Benzothiazoles: How Relevant in Cancer Drug Design Strategy?
Anti-Cancer Agents in Medicinal Chemistry Impact of Drug Metabolism/Pharmacokinetics and its Relevance Considering Traditional Medicine-based Anti-COVID-19 Drug Research
Current Drug Metabolism Nematicidal Activity of Sprio and Bridged Heterocyclic Neonicotinoid Analogues against Meloidogyne incognita
Letters in Drug Design & Discovery Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design A SAR Study: Evaluation of Bromo Derivatives of 8-Substituted Quinolines as Novel Anticancer Agents
Letters in Drug Design & Discovery